secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001213900-25-064869
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Aldeyra's reproxalap NDA resubmission for dry eye disease; PDUFA Dec 16, 2025
--------------------------------------------------------------------------------

- FDA accepted for review the resubmitted NDA for topical ocular reproxalap, a first-in-class candidate for dry eye disease.
- PDUFA target action date set for December 16, 2025.
- Resubmission includes a single clinical trial that met primary endpoint of reducing ocular discomfort vs vehicle control.
- Reproxalap is the only dry eye investigational therapy to show acute activity reducing ocular discomfort and redness in pivotal trials simulating disease flares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000121390025064869/0001213900-25-064869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000121390025064869/ea0249257-8k_aldeyra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-064869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer